塞来昔布、美洛昔康和对乙酰氨基酚治疗老年大骨节病（KBD）患者的疗效。
Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients.
机构信息
Department of Immunology and Rheumatology, Sichuan University, Chengdu, People's Republic of China.
出版信息
Int Orthop. 2011 Sep;35(9):1409-14. doi: 10.1007/s00264-010-1062-0. Epub 2010 Jun 13.
Abstract
The objective of this study was to compare the efficacy and tolerability of celecoxib, meloxicam and paracetamol in late Kashin-Beck disease. Adults (n = 168) with Kashin-Beck disease were randomised in clusters to receive six week courses of celecoxib 200 mg once daily, meloxicam 7.5 mg once daily or paracetamol 300 mg three times daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Celecoxib and meloxicam were efficacious in relieving pain and improving stiffness, but unable to improve physical function after six weeks. Paracetamol was efficacious in relieving pain, but unable to improve morning stiffness and physical function after six weeks. Celecoxib and meloxicam provide predictable and sustained relief from pain and stiffness. Paracetamol can relieve the pain. None of the treatments improved impaired physical function in Kashin-Beck disease.
摘要
本研究旨在比较塞来昔布、美洛昔康和对乙酰氨基酚治疗晚发性大骨节病的疗效和耐受性。将 168 例大骨节病患者按簇随机分为塞来昔布 200mg 每日 1 次、美洛昔康 7.5mg 每日 1 次和对乙酰氨基酚 300mg 每日 3 次 6 周疗程组。疗效评估包括关节疼痛总强度和西安大略和麦克马斯特大学骨关节炎指数亚量表；通过不良事件和医生报告评估耐受性。塞来昔布和美洛昔康可有效缓解疼痛和改善僵硬，但 6 周后无法改善躯体功能。对乙酰氨基酚可有效缓解疼痛，但 6 周后无法改善晨僵和躯体功能。塞来昔布和美洛昔康可提供可预测和持续的疼痛和僵硬缓解。对乙酰氨基酚可以缓解疼痛。治疗均无法改善大骨节病患者的躯体功能受损。
相似文献
1
Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients.塞来昔布、美洛昔康和对乙酰氨基酚治疗老年大骨节病（KBD）患者的疗效。
Int Orthop. 2011 Sep;35(9):1409-14. doi: 10.1007/s00264-010-1062-0. Epub 2010 Jun 13.
2
A randomized, single-blind comparison of the efficacy and tolerability of hyaluronate acid and meloxicam in adult patients with Kashin-Beck disease of the knee.透明质酸与美洛昔康治疗成人膝关节大骨节病的随机、单盲、对照疗效及耐受性比较
Clin Rheumatol. 2012 Jul;31(7):1079-86. doi: 10.1007/s10067-012-1979-3. Epub 2012 Apr 3.
3
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.罗非昔布、塞来昔布和对乙酰氨基酚治疗膝骨关节炎的疗效：一项随机试验。
JAMA. 2002 Jan 2;287(1):64-71. doi: 10.1001/jama.287.1.64.
4
Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials.塞来昔布与缓释对乙酰氨基酚治疗骨关节炎的比较：一系列单病例试验
Rheumatology (Oxford). 2007 Jan;46(1):135-40. doi: 10.1093/rheumatology/kel195. Epub 2006 Jun 15.
5
Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.患者对安慰剂、对乙酰氨基酚或塞来昔布疗效的偏好研究（PACES）：两项针对膝关节或髋关节骨关节炎患者的随机、双盲、安慰剂对照、交叉临床试验。
Ann Rheum Dis. 2004 Aug;63(8):931-9. doi: 10.1136/ard.2003.020313. Epub 2004 Apr 13.
6
Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study.低剂量速溶型美洛昔康治疗骨关节炎疼痛的疗效与安全性：一项为期12周的3期研究。
Curr Med Res Opin. 2015 Dec;31(12):2331-43. doi: 10.1185/03007995.2015.1112772.
7
[Tolerance to celecoxib and meloxicam in patients with intolerance to nonsteroidal anti-inflammatory drugs].[对非甾体抗炎药不耐受患者对塞来昔布和美洛昔康的耐受性]
An Med Interna. 2008 Apr;25(4):163-7. doi: 10.4321/s0212-71992008000400003.
8
Kashin-Beck disease in Sichuan, China: report of a pilot open therapeutic trial.中国四川大骨节病：一项开放性治疗试验的初步报告。
J Clin Rheumatol. 2012 Jan;18(1):8-14. doi: 10.1097/RHU.0b013e31823e3a3b.
9
10
Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs.塞来昔布治疗因 NSAIDs 引起的复发性肾病综合征患者的安全性。
Clin Drug Investig. 2011;31(5):351-5. doi: 10.1007/BF03256934.
引用本文的文献
1
The Long-term Efficacy of Total Knee Arthroplasty on End-stage Kashin-Beck Disease of the Knee in Highland Tibetan Areas Patients: A Retrospective Study with 10-Year Follow-up.《高原藏族地区膝关节晚期大骨节病全膝关节置换术的长期疗效：一项 10 年随访的回顾性研究》
Orthop Surg. 2024 Jun;16(6):1300-1307. doi: 10.1111/os.14068. Epub 2024 Apr 21.
2
Differential expression of cyclins CCNB1 and CCNG1 is involved in the chondrocyte damage of kashin-beck disease.细胞周期蛋白CCNB1和CCNG1的差异表达与大骨节病软骨细胞损伤有关。
Front Genet. 2022 Dec 14;13:1053685. doi: 10.3389/fgene.2022.1053685. eCollection 2022.
3
Progress of Selenium Deficiency in the Pathogenesis of Arthropathies and Selenium Supplement for Their Treatment.硒缺乏在关节病发病机制中的研究进展及其硒补充治疗。
Biol Trace Elem Res. 2022 Oct;200(10):4238-4249. doi: 10.1007/s12011-021-03022-4. Epub 2021 Nov 15.
4
Long-term outcomes of arthroscopic debridement of the knee in adults with Kashin-Beck disease: an 18-year follow-up.成人膝关节关节镜下清理术治疗大骨节病的 18 年随访结果。
J Int Med Res. 2021 Oct;49(10):3000605211050781. doi: 10.1177/03000605211050781.
5
Dysregulation of Transcription Profile of Selenoprotein in Patients with Kashin-Beck Disease and Its Effect on Se Deficiency-Induced Chondrocyte Apoptosis.硒蛋白转录谱失调与大骨节病患者及其对硒缺乏诱导软骨细胞凋亡的影响。
Biol Trace Elem Res. 2022 Apr;200(4):1508-1517. doi: 10.1007/s12011-021-02772-5. Epub 2021 Jun 26.
6
Pathway-based network analyses and candidate genes associated with Kashin-Beck disease.基于通路的与大骨节病相关的网络分析及候选基因
Medicine (Baltimore). 2019 May;98(18):e15498. doi: 10.1097/MD.0000000000015498.
7
Outcomes of total knee arthroplasty in the adult Kashin-Beck disease with severe osteoarthritis.成人膝关节病伴严重骨关节炎全膝关节置换术的结果。
Int Orthop. 2019 Feb;43(2):323-331. doi: 10.1007/s00264-018-4029-1. Epub 2018 Jul 3.
8
Serum levels of PIICP, PIIANP, and PIIBNP are decreased in patients with an endemic osteochondropathy, Kashin-Beck disease.在患有地方性骨软骨病——大骨节病的患者中，血清中Ⅱ型前胶原羧基端前肽（PIICP）、Ⅱ型前胶原氨基端前肽（PIIANP）和Ⅱ型脑钠肽（PIIBNP）的水平降低。
J Orthop Surg Res. 2018 May 29;13(1):128. doi: 10.1186/s13018-018-0840-z.
9
Effects of five types of selenium supplementation for treatment of Kashin-Beck disease in children: a systematic review and network meta-analysis.五种补硒方式对儿童大骨节病治疗效果的系统评价与网状Meta分析
BMJ Open. 2018 Mar 6;8(3):e017883. doi: 10.1136/bmjopen-2017-017883.
10
Kashin-Beck disease involving the ankles.累及踝关节的大骨节病。
Radiol Case Rep. 2015 Nov 6;6(3):544. doi: 10.2484/rcr.v6i3.544. eCollection 2011.
本文引用的文献
1
Effects of physical environment on the evolution of Kashin-Beck disease in Tibet.西藏自然环境对大骨节病病情演变的影响
Int Orthop. 2009 Aug;33(4):1085-8. doi: 10.1007/s00264-009-0738-9. Epub 2009 Mar 17.
2
Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial.塞来昔布每日一次给药方案治疗骨关节炎：一项随机对照试验。
J Clin Rheumatol. 2000 Apr;6(2):65-74. doi: 10.1097/00124743-200004000-00002.
3
Selenium and iodine supplementation of rural Tibetan children affected by Kashin-Beck osteoarthropathy.对受大骨节病影响的西藏农村儿童补充硒和碘
Am J Clin Nutr. 2003 Jul;78(1):137-44. doi: 10.1093/ajcn/78.1.137.
4
Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.对使用选择性环氧化酶-2抑制剂或传统非甾体抗炎药的老年患者上消化道出血的观察性研究。
BMJ. 2002 Sep 21;325(7365):624. doi: 10.1136/bmj.325.7365.624.
5
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.塞来昔布治疗骨关节炎和类风湿关节炎的疗效、耐受性及上消化道安全性：随机对照试验的系统评价
BMJ. 2002 Sep 21;325(7365):619. doi: 10.1136/bmj.325.7365.619.
6
The coxibs, selective inhibitors of cyclooxygenase-2.昔布类药物，即环氧化酶-2的选择性抑制剂。
N Engl J Med. 2001 Aug 9;345(6):433-42. doi: 10.1056/NEJM200108093450607.
7
Effects of physical therapy on patients with Kashin-Beck disease in Tibet.物理治疗对西藏大骨节病患者的影响。
Int Orthop. 2001;25(3):191-3. doi: 10.1007/s002640000206.
8
Kashin-Beck disease and drinking water in Central Tibet.西藏中部的大骨节病与饮用水
Int Orthop. 2001;25(3):167-9. doi: 10.1007/s002640000194.
9
The prevalence of mycotoxins in Kashin-Beck disease.大骨节病中霉菌毒素的流行情况。
Int Orthop. 2001;25(3):159-61. doi: 10.1007/s002640100240.
10
The anatomical distribution of radiological abnormalities in Kashin-Beck disease in Tibet.西藏大骨节病放射学异常的解剖分布
Int Orthop. 2001;25(3):142-6. doi: 10.1007/s002640100236.
Zotero 插件